These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 16470820

  • 1. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
    Raedler TJ, Jahn H, Goedeken B, Gescher DM, Kellner M, Wiedemann K.
    Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
    [Abstract] [Full Text] [Related]

  • 2. Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis.
    Raedler TJ, Jahn H, Goedeken B, Gescher DM, Kellner M, Wiedemann K.
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):482-6. PubMed ID: 13680163
    [Abstract] [Full Text] [Related]

  • 3. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
    Zwanzger P, Eser D, Aicher S, Schüle C, Baghai TC, Padberg F, Ella R, Möller HJ, Rupprecht R.
    Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
    [Abstract] [Full Text] [Related]

  • 4. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
    Demiralay C, Jahn H, Kellner M, Yassouridis A, Wiedemann K.
    World J Biol Psychiatry; 2012 Oct; 13(7):526-34. PubMed ID: 22111662
    [Abstract] [Full Text] [Related]

  • 5. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
    Ströhle A, Holsboer F, Rupprecht R.
    Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
    [Abstract] [Full Text] [Related]

  • 6. Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects.
    Abelson JL, Liberzon I, Young EA, Khan S.
    Arch Gen Psychiatry; 2005 Jun; 62(6):668-75. PubMed ID: 15939844
    [Abstract] [Full Text] [Related]

  • 7. Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4.
    Eser D, Leicht G, Baghai T, Pogarell O, Schüle C, Karch S, Nothdurfter C, Rupprecht R, Mulert C.
    J Psychiatr Res; 2009 Jan; 43(4):393-400. PubMed ID: 18534623
    [Abstract] [Full Text] [Related]

  • 8. CO2 challenge results in hypothalamic-pituitary-adrenal activation in healthy volunteers.
    van Duinen MA, Schruers KR, Maes M, Griez EJ.
    J Psychopharmacol; 2005 May; 19(3):243-7. PubMed ID: 15888509
    [Abstract] [Full Text] [Related]

  • 9. Effects of the cortisol synthesis inhibitor metyrapone on the response to carbon dioxide challenge in panic disorder.
    Belgorodsky A, Knyazhansky L, Loewenthal U, Arbelle J, Cohen H, Benjamin J.
    Depress Anxiety; 2005 May; 21(3):143-8. PubMed ID: 16001448
    [Abstract] [Full Text] [Related]

  • 10. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.
    Zwanzger P, Baghai TC, Schuele C, Ströhle A, Padberg F, Kathmann N, Schwarz M, Möller HJ, Rupprecht R.
    Neuropsychopharmacology; 2001 Nov; 25(5):699-703. PubMed ID: 11682253
    [Abstract] [Full Text] [Related]

  • 11. The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects.
    Ströhle A, Graetz B, Scheel M, Wittmann A, Feller C, Heinz A, Dimeo F.
    J Psychiatr Res; 2009 Aug; 43(12):1013-7. PubMed ID: 19289240
    [Abstract] [Full Text] [Related]

  • 12. Effects of propranolol on symptom and endocrine responses to pentagastrin.
    Khan S, Liberzon I, Abelson JL.
    Psychoneuroendocrinology; 2004 Oct; 29(9):1163-71. PubMed ID: 15219640
    [Abstract] [Full Text] [Related]

  • 13. Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms?
    Demiralay C, Agorastos A, Yassouridis A, Jahn H, Wiedemann K, Kellner M.
    Psychoneuroendocrinology; 2017 Feb; 76():14-18. PubMed ID: 27871026
    [Abstract] [Full Text] [Related]

  • 14. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder.
    Katzman MA, Koszycki D, Bradwejn J.
    Depress Anxiety; 2004 Feb; 20(2):51-8. PubMed ID: 15390214
    [Abstract] [Full Text] [Related]

  • 15. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
    Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A.
    Biol Psychiatry; 1995 Dec 01; 38(11):742-6. PubMed ID: 8580227
    [Abstract] [Full Text] [Related]

  • 16. Effects of intravenous caffeine administered to healthy males during sleep.
    Lin AS, Uhde TW, Slate SO, McCann UD.
    Depress Anxiety; 1997 Dec 01; 5(1):21-8. PubMed ID: 9250437
    [Abstract] [Full Text] [Related]

  • 17. Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam.
    Fries E, Hellhammer DH, Hellhammer J.
    Psychoneuroendocrinology; 2006 Nov 01; 31(10):1278-88. PubMed ID: 17097811
    [Abstract] [Full Text] [Related]

  • 18. HPA axis activity in patients with panic disorder: review and synthesis of four studies.
    Abelson JL, Khan S, Liberzon I, Young EA.
    Depress Anxiety; 2007 Nov 01; 24(1):66-76. PubMed ID: 16845643
    [Abstract] [Full Text] [Related]

  • 19. Panic induction with cholecystokinin-tetrapeptide (CCK-4) Increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers.
    Eser D, di Michele F, Zwanzger P, Pasini A, Baghai TC, Schüle C, Rupprecht R, Romeo E.
    Neuropsychopharmacology; 2005 Jan 01; 30(1):192-5. PubMed ID: 15467707
    [Abstract] [Full Text] [Related]

  • 20. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
    Wiedemann K, Jahn H, Yassouridis A, Kellner M.
    Arch Gen Psychiatry; 2001 Apr 01; 58(4):371-7. PubMed ID: 11296098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.